Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proglumetacin SCHEMBL29384391 | 1.00 | PTGS2 (0.59) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL19642980 | 0.97 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL1650599 | 0.97 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL99165 | 0.97 | PTGS2 (0.56) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL2070226 | 0.97 | PTGS2 (0.55) | PTGS2PTGS1 | |
| Proglumetacin SCHEMBL28086382 | 0.97 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL5077578 | 0.91 | PTGS2 (0.57) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL4094289 | 0.91 | PTGS2 (0.52) | PTGS2 | |
| Proglumetacin SCHEMBL13724384 | 0.91 | PTGS2 (0.49) | PTGS2HTR1APKMPTGS1GLO1 | |
| Proglumetacin SCHEMBL5482765 | 0.89 | PTGS2 (0.47) | PTGS2HTR1APKMPTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4877 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2024105529-A1 | CHEMICAL DISBUDDING OF LIVESTOCK | MASSEY UNIVERSITY (NZ) | 2024-05-23 | — | — | WO | claimed |
| EP-4340884-A1 | TREATMENT OF INFECTIONS IN AND AROUND THE EYE | University of Miami (US) | 2024-03-27 | — | — | EP | claimed |
| WO-2024027794-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | 哈尔滨市康隆药业有限责任公司 | 2024-02-08 | — | — | WO | claimed |
| US-20240041935-A1 | PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS | CREATIVE MEDICAL TECHNOLOGIES, INC. (US) | 2024-02-08 | — | — | US | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| WO-2022245950-A1 | TREATMENT OF INFECTIONS IN AND AROUND THE EYE | UNIVERSITY OF MIAMI (US) | 2022-11-24 | — | — | WO | claimed |
| US-5818002-A | Pressure change warning switch | CTS CORPORATION (US) | 1998-10-06 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| WO-1997037680-A1 | MACROMOLECULAR COMPLEXES FOR DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 1997-10-16 | — | — | WO | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |